8 results on '"Yuanlu Shuai"'
Search Results
2. Automated choroid segmentation of three-dimensional SD-OCT images by incorporating EDI-OCT images.
- Author
-
Qiang Chen 0004, Sijie Niu, Wangyi Fang, Yuanlu Shuai, Wen Fan, Songtao Yuan, and Qinghuai Liu
- Published
- 2018
- Full Text
- View/download PDF
3. Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
- Author
-
Jun-Jun Wang, Qinghuai Liu, Jun-Long Huang, Jia Li, Yu-Zhi Ding, Yuanlu Shuai, Hai-Tao Pan, and Zizhong Hu
- Subjects
medicine.medical_specialty ,Medicine (General) ,Prospective Clinical Research Report ,Combination therapy ,genetic structures ,Visual Acuity ,Angiogenesis Inhibitors ,Pilot Projects ,Traditional Chinese medicine ,Biochemistry ,choroidal neovascularization ,combination therapy ,03 medical and health sciences ,Macular Degeneration ,traditional Chinese medicine ,0302 clinical medicine ,R5-920 ,Ophthalmology ,Ranibizumab ,medicine ,Humans ,Prospective Studies ,age-related macular degeneration ,business.industry ,Biochemistry (medical) ,Capsule ,Cell Biology ,General Medicine ,Exudative age-related macular degeneration ,Fufang xueshuantong ,eye diseases ,Choroidal neovascularization ,Treatment Outcome ,Intravitreal Injections ,030221 ophthalmology & optometry ,sense organs ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Tomography, Optical Coherence ,medicine.drug ,Drugs, Chinese Herbal - Abstract
Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration. Methods This prospective, randomized, controlled, pilot study included 38 eyes from 38 patients with exudative age-related macular degeneration (AMD) that were randomly allocated into two cohorts of 19 eyes each: ranibizumab (Cr) and ranibizumab plus cFXST (Cfr). All patients received three monthly injections of ranibizumab. Patients in Cfr also received daily oral supplementation of cFXST. Best corrected visual acuity (BCVA) and thickness of the choroidal neovascularization-pigment epithelial detachment (CNV-PED) complex (measured by optical coherence tomography) were recorded at baseline and at 1 and 3 months after the first intravitreal injection of ranibizumab. Results In the Cfr, the CNV-PED complex thickness was reduced by 31.7% and 36.1% at 1 and 3 months, respectively; these reductions were significantly greater than the 19.7% and 24.2% reductions in the Cr. BCVA improvement was significantly greater in the Cfr than in the Cr after 3 months; the proportion of patients with functional response was also greater in the Cfr than in the Cr (16/16 vs. 8/17). Conclusion Oral cFXST increases the efficacy of short-term ranibizumab treatment for exudative AMD.
- Published
- 2020
4. Automated choroid segmentation of three-dimensional SD-OCT images by incorporating EDI-OCT images
- Author
-
Qinghuai Liu, Wen Fan, Sijie Niu, Wangyi Fang, Songtao Yuan, Yuanlu Shuai, and Qiang Chen
- Subjects
genetic structures ,Computer science ,Feature vector ,Image registration ,Health Informatics ,01 natural sciences ,010309 optics ,Automation ,Macular Degeneration ,03 medical and health sciences ,chemistry.chemical_compound ,Imaging, Three-Dimensional ,0302 clinical medicine ,Optical coherence tomography ,0103 physical sciences ,medicine ,Humans ,Segmentation ,Computer vision ,Diabetic Retinopathy ,medicine.diagnostic_test ,Choroid ,business.industry ,Retinal ,Diabetic retinopathy ,Macular degeneration ,Image Enhancement ,medicine.disease ,eye diseases ,Computer Science Applications ,medicine.anatomical_structure ,chemistry ,Case-Control Studies ,030221 ophthalmology & optometry ,sense organs ,Artificial intelligence ,business ,Tomography, Optical Coherence ,Software - Abstract
Background and Objective The measurement of choroidal volume is more related with eye diseases than choroidal thickness, because the choroidal volume can reflect the diseases comprehensively. The purpose is to automatically segment choroid for three-dimensional (3D) spectral domain optical coherence tomography (SD-OCT) images. Methods We present a novel choroid segmentation strategy for SD-OCT images by incorporating the enhanced depth imaging OCT (EDI-OCT) images. The down boundary of the choroid, namely choroid-sclera junction (CSJ), is almost invisible in SD-OCT images, while visible in EDI-OCT images. During the SD-OCT imaging, the EDI-OCT images can be generated for the same eye. Thus, we present an EDI-OCT-driven choroid segmentation method for SD-OCT images, where the choroid segmentation results of the EDI-OCT images are used to estimate the average choroidal thickness and to improve the construction of the CSJ feature space of the SD-OCT images. We also present a whole registration method between EDI-OCT and SD-OCT images based on retinal thickness and Bruch's Membrane (BM) position. The CSJ surface is obtained with a 3D graph search in the CSJ feature space. Results Experimental results with 768 images (6 cubes, 128 B-scan images for each cube) from 2 healthy persons, 2 age-related macular degeneration (AMD) and 2 diabetic retinopathy (DR) patients, and 210 B-scan images from other 8 healthy persons and 21 patients demonstrate that our method can achieve high segmentation accuracy. The mean choroid volume difference and overlap ratio for 6 cubes between our proposed method and outlines drawn by experts were −1.96µm3 and 88.56%, respectively. Conclusions Our method is effective for the 3D choroid segmentation of SD-OCT images because the segmentation accuracy and stability are compared with the manual segmentation.
- Published
- 2018
- Full Text
- View/download PDF
5. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy
- Author
-
Xinghong Sun, Qinghuai Liu, Jia Li, Weizhong Ge, Yuanlu Shuai, Wangyi Fang, and Songtao Yuan
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Visual Acuity ,Administration, Oral ,Spironolactone ,Clinical study ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,0302 clinical medicine ,Acute central serous chorioretinopathy ,Ophthalmology ,Humans ,Medicine ,In patient ,Prospective Studies ,Fluorescein Angiography ,Trial registration ,Mineralocorticoid Receptor Antagonists ,business.industry ,Subretinal Fluid ,Outcome measures ,Middle Aged ,Sensory Systems ,Surgery ,Observational Studies as Topic ,Treatment Outcome ,030104 developmental biology ,medicine.anatomical_structure ,Central Serous Chorioretinopathy ,chemistry ,Acute Disease ,030221 ophthalmology & optometry ,Female ,Choroid ,Subretinal fluid ,business ,Tomography, Optical Coherence ,Follow-Up Studies - Abstract
PurposeTo evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC).MethodsThis is a prospective, randomised controlled clinical study. Thirty patients with acute CSC were the participants, including 18 patients who were treated with spironolactone (40 mg orally, twice daily) for 2 months in the experimental group and 12 patients who received observation in the control group. Main outcome measures included the proportion of eyes achieving complete resolution of subretinal fluid (SRF), changes in central macular thickness (CMT), the height of SRF (SRFH), best corrected visual acuity (BCVA) and subfoveal choroidal thickness (SFCT). The follow-up period was 2 months.ResultsComplete resolution of SRF was achieved in 55.6% (10/18) and 8.3% (1/12) of the eyes in the treatment group and the control group, respectively, at 2 months (p=0.018). The mean CMT and SRFH decreased significantly at each visit in both groups (pConclusionsOral spironolactone is more effective with a faster absorption of SRF than observations. It is a promising treatment for acute CSC.Trial registration numberChiCTR-IPR-16008428, Results.
- Published
- 2017
- Full Text
- View/download PDF
6. Focal choroidal excavation and a traumatic macular hole secondary to accidental Q-switched Nd:YAG laser
- Author
-
Xianglei Chen, Jia Li, Weizhong Ge, Wangyi Fang, Songtao Yuan, Qinghuai Liu, and Yuanlu Shuai
- Subjects
Adult ,Pars plana ,medicine.medical_specialty ,Visual acuity ,genetic structures ,medicine.medical_treatment ,Visual Acuity ,Biophysics ,Vitrectomy ,Lasers, Solid-State ,Dermatology ,law.invention ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Optical coherence tomography ,law ,Ophthalmology ,medicine ,Humans ,Pharmacology (medical) ,Macular hole ,medicine.diagnostic_test ,business.industry ,Retinal ,Retinal Perforations ,medicine.disease ,Laser ,eye diseases ,Surgery ,medicine.anatomical_structure ,Oncology ,chemistry ,Nd:YAG laser ,030221 ophthalmology & optometry ,Female ,sense organs ,medicine.symptom ,business ,Tomography, Optical Coherence - Abstract
Today, the widespread use of laser instruments in various fields has resulted in many accidental retinal injuries. Here we describe a rare clinical case of full-thickness macular hole (MH) and focal choroidal excavation (FCE) caused by a 1064-nm Q-switched Nd:YAG laser. After pars plana vitrectomy and the following 14 months, consecutive optical coherence tomography imagings showed closure of the MH. Visual acuity improved even in the absence of the outer retina and in the presence of FCE. We speculate that different focusing effects of the unexpected Nd:YAG lasers which target different levels of retinal tissue generate diverse prognosis.
- Published
- 2017
- Full Text
- View/download PDF
7. New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion
- Author
-
Jia Li, Yannis M. Paulus, Qinghuai Liu, Wangyi Fang, Songtao Yuan, and Yuanlu Shuai
- Subjects
medicine.medical_specialty ,business.industry ,MEDLINE ,Disease ,Review Article ,medicine.disease ,Surgery ,Natural history ,Pathogenesis ,03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,lcsh:Ophthalmology ,lcsh:RE1-994 ,030221 ophthalmology & optometry ,medicine ,Branch retinal vein occlusion ,Intensive care medicine ,business ,030217 neurology & neurosurgery - Abstract
For years, branch retinal vein occlusion is still a controversial disease in many aspects. An increasing amount of data is available regarding classification, pathogenesis, risk factors, natural history, and therapy of branch retinal vein occlusion. Some of the conclusions may even change our impression of branch retinal vein occlusion. It will be beneficial for our doctors to get a deeper understanding of this disease and improve the treatment skills. The aims of this review is to collect the information above and report new ideas especially from the past a few years.
- Published
- 2016
8. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
- Author
-
Xinghong Sun, Yuanlu Shuai, Wangyi Fang, Jia Li, Weizhong Ge, Songtao Yuan, and Qinghuai Liu
- Abstract
Purpose To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC). Methods This is a prospective, randomised controlled clinical study. Thirty patients with acute CSC were the participants, including 18 patients who were treated with spironolactone (40 mg orally, twice daily) for 2 months in the experimental group and 12 patients who received observation in the control group. Main outcome measures included the proportion of eyes achieving complete resolution of subretinal fluid (SRF), changes in central macular thickness (CMT), the height of SRF (SRFH), best corrected visual acuity (BCVA) and subfoveal choroidal thickness (SFCT). The follow-up period was 2 months. Results Complete resolution of SRF was achieved in 55.6% (10/18) and 8.3% (1/12) of the eyes in the treatment group and the control group, respectively, at 2 months (p=0.018). The mean CMT and SRFH decreased significantly at each visit in both groups (p<0.05), and there was significant difference between the two groups at 2 months (p<0.05 and p<0.05, respectively). BCVA (in logarithm of the minimum angle of resolution; mean) improved in both groups at 2 months (p<0.05). In the treatment group, the mean baseline SFCT significantly decreased from 502.50±87.38 μm to 427.44±74.37 μm at 2 months (p<0.01), while the change from baseline (from 480.33±102.38 μm to 463.75±100.63 μm) was not significant in the control group (p=0.195). But the differences between the two groups in BCVA and SFCT were not significant. Conclusions Oral spironolactone is more effective with a faster absorption of SRF than observations. It is a promising treatment for acute CSC. Trial registration number ChiCTR-IPR-16008428, Results. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.